PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Drug to reverse breast cancer spread in development

Compound trialed on mice showed a complete halt in spread of metastatic tumors

2014-01-27
(Press-News.org) Contact information: Tomas Llewelyn Barrett
BarrettTL1@cardiff.ac.uk
44-795-079-253
Cardiff University
Drug to reverse breast cancer spread in development Compound trialed on mice showed a complete halt in spread of metastatic tumors

Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells.

The vast majority of deaths from cancer result from its progressive spread to vital organs, known as metastasis. In breast cancer up to 12,000 patients a year develop this form of the disease, often several years after initial diagnosis of a breast lump.

In a recent series of studies researchers identified a previously unknown critical role for a potential cancer causing gene, Bcl3, in metastatic breast cancer.

"We showed that suppressing this gene reduced the spread of cancer by more than 80%," said Dr Richard Clarkson from Cardiff University's European Cancer Stem Cell Research Institute.

"Our next goal was to then find a way to suppress Bcl3 pharmacologically. Despite great improvements in therapy of early stage breast cancer, the current therapeutic options for patients with late stage metastatic disease are limited.

"There is therefore a clear unmet clinical need to identify new drugs to reverse or at least to slow down disease progression" he added.

Dr Clarkson and his team joined up with researchers Dr Andrea Brancale and Dr Andrew Westwell from the Cardiff University School of Pharmacy and Pharmaceutical Sciences, to develop small chemical inhibitors of the Bcl3 gene.

Computer aided modeling of how the Bcl3 gene functions inside the cell allowed the group to identify a pocket on the surface of Bcl3 essential for its function. By screening a virtual compound library for chemicals that could fit inside this pocket, using state-of-the-art computer software, they identified a drug candidate that potently inhibits Bcl3.

The compound was then trialed on mice with metastatic disease. The resulting effect was that the drug completely inhibited the development of the mice's metastatic tumours.

With financial backing from Tiziana Pharmaceuticals*, work is now underway to progress the compound to clinical trials. The aim is to develop a therapeutic agent capable of blocking metastatic disease in breast cancer and a variety of tumour types.

INFORMATION:

END



ELSE PRESS RELEASES FROM THIS DATE:

Blue eyes and dark skin, that's how the European hunter-gatherer looked

2014-01-27
La Braña 1, name used to baptize a 7,000 years ...

Engineers teach old chemical new tricks to make cleaner fuels, fertilizers

2014-01-27
University researchers from two continents ...

Sensitivity of carbon cycle to tropical temperature variations has doubled, research shows

2014-01-27
The tropical carbon cycle has become ...

Cleveland Clinic researchers discover process that turns 'good cholesterol' bad

2014-01-27
Cleveland: Cleveland Clinic researchers have discovered the process by ...

Shortening guide RNA markedly improves specificity of CRISPR-Cas nucleases

2014-01-27
A simple adjustment to a powerful gene-editing tool may be able to improve its specificity. In a report receiving advance online publication in Nature Biotechnology, Massachusetts ...

How does the brain create sequences?

2014-01-27
When you learn how to play the piano, first you have to learn notes, scales and chords and only then will you be able to play a piece of music. The same ...

Long-lived breast stem cells could retain cancer legacy

2014-01-27
Researchers from Melbourne's Walter and Eliza Hall Institute have discovered that breast stem cells and their 'daughters' have a much longer lifespan than previously thought, and are active in puberty ...

Music therapy's positive effects on young cancer patients' coping skills, social integration

2014-01-27
A new study has found that adolescents and young adults undergoing cancer treatment gain coping skills and resilience-related outcomes when they participate in a therapeutic music ...

Quality improvement initiative improves asthma outcomes in teens

2014-01-27
Researchers at Cincinnati Children's Hospital Medical Center have successfully carried out what is believed to be the first initiative conducted exclusively among teenagers to show ...

After the gunshot: Hospitalizations for firearm injuries prevalent among children

2014-01-27
About 20 children per day in the United States are injured by firearms seriously enough to require hospitalization, and more than 6% of these children die from their injuries, according ...

LAST 30 PRESS RELEASES:

Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer

Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer

What is the extent of disparities in cancer clinical trials among low- and middle-income countries?

Invisible poison: Airborne mercury from gold mining is contaminating African food crops, new study warns

Nearly half of Finns with chronic conditions find medication therapy a burden

Do animals fall for optical illusions? What fish and birds can teach us about perception

New guideline emphasizes conversations about mood, mental health between patients and clinicians

Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma

Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer

ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy

Drug combo cuts risk of death in advanced prostate cancer by 40%

ADC improves outcomes for patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors

Novel treatment combination improves progression-free survival in metastatic, estrogen-receptor-positive HER-2-negative breast cancer

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients

New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease

Sylvester Cancer Tip Sheet for October 2025

Three science and technology leaders elected to Hertz Foundation Board of Directors

Jump Trading CSO Kevin Bowers elected to Hertz Foundation Board of Directors

Former Inscripta CEO Sri Kosaraju elected to Hertz Foundation Board of Directors

Citadel’s Jordan Chetty elected to Hertz Foundation Board of Directors

McGill research flags Montreal snow dump, inactive landfills as major methane polluters

A lightweight and rapid bidirectional search algorithm

Eighty-five years of big tree history available in one place for the first time

MIT invents human brain model with six major cell types to enable personalized disease research, drug discovery

Health and economic air quality co-benefits of stringent climate policies

How immune cells deliver their deadly cargo

How the brain becomes a better listener: How focus enhances sound processing

Processed fats found in margarines unlikely to affect heart health

[Press-News.org] Drug to reverse breast cancer spread in development
Compound trialed on mice showed a complete halt in spread of metastatic tumors